Mayne Pharma Group Limited (ASX:MYX) is trading at a 40% discount to its intrinsic value

In this article I am going to calculate the intrinsic value of Mayne Pharma Group (ASX:MYX) by estimating the Future Cash Flows and discounting them to their present value. A discounted cash flow (DCF) analysis represents the net present value (NPV) of projected cash flows to a stock. Don’t get put off by the jargon, the math behind it is actually quite straightforward.

Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Please also note that this article was written in May 2017 so be sure check out the updated calculation by following the link below. Check out our latest analysis for Mayne Pharma Group

We are going to use a two stage model that takes into account two stages of growth. The first stage may have a high growth rate and the second stage is usually assumed to have a stable growth rate. To start off with we need to estimate the next 5 years of cash flows, where possible I use analysts estimates but when these aren’t available I have extrapolated the previous Free Cash Flow (FCF) from the year before. For this growth rate I used the average annual growth rate over the past 5 years, but capped to a reasonable level. The sum of these cash flows is then discounted to today’s value.

Mayne Pharma Group (ASX:MYX) Intrinsic Value May 19th 17
Mayne Pharma Group (ASX:MYX) Intrinsic Value May 19th 17

The calculation

Please note that the numbers here are in millions apart from the per share values.

5-year cash flow estimate

2017 2018 2019 2020 2021
Levered FCF (AUD, Millions) $-109.40 $130.15 $151.10 $176.79 $205.07
Source Analyst x1 Analyst x2 Analyst x1 Extrapolated @ (17%, capped from 63.1%) Extrapolated @ (16%, capped from 63.1%)
Present Value Discounted @ 8.62% $-100.71 $110.30 $117.89 $126.98 $135.60

Present value of next 5 years cash flows: $390

The 2nd stage is also known as Terminal Value, this is the cash flows to the business after the 1st stage. For a number of reasons a very conservative rate is used that cannot exceed that of the GDP. In this case I have used the 10 year government bond rate (2.6%). In the same way as with the 5 year ‘growth’ period we discount this to today’s value.

Terminal Value

Terminal Value = FCF2021 × (1 + g) ÷ (Discount Rate – g)

Terminal Value = $205 × (1 + 2.6%) ÷ (8.6% – 2.6%)

Terminal value based on the Perpetuity Method where growth (g) = 2.6%: $3,492

Present value of terminal value: $2,309

The total value or equity value is then the sum of of the present value of the cash flows.

Equity Value

Equity Value (Total value) = Present value of next 5 years cash flows + terminal value = $390 + $2,309 = $2,699

In the final step we divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) or ADR then we use the equivalent number.

Value = Total value / Shares Outstanding ($2,699.28 / 1,510.99)

Value per share: $1.79

Now when we compare the intrinsic value of 1.79 to the current share price of $1.065 we see Mayne Pharma Group (ASX:MYX) is quite good value at a 40% discount to what it is available for right now.

Important assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Mayne Pharma Group as potential investors the Cost of Equity is used as the discount rate, not the Cost of Capital (or Weighed Average Cost of Capital/ WACC) which accounts for debt.

In this calculation I’ve used 8.6% and this is based on a Levered Beta of 0.814. I’m not going to go into how I calculate the Levered Beta in detail, I used the ‘Bottom up Beta’ method based on the comparable businesses, I also impose a limit between 0.8 and 2 which is a reasonable range for a stable business. Google this if you want to learn more.

Final Words

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. Is Mayne Pharma Group in a healthy financial condition? What is the reason for the share price to differ from the intrinsic value? See our latest FREE analysis to find out!

PS. The Simply Wall St app conducts a discounted cash flow for every stock on the ASX every 6 hours. If you want to find the calculation for another other stock just search here.